Breast Cancer

The combination of sacituzumab with pembrolizumab did not lead to a decline in physical functioning or quality of life in patients with metastatic TNBC.

The DESTINY-Breast11 trial found neoadjuvant T-DXd followed by THP improved pathologic complete response vs ddAC-THP in high-risk, HER2-positive early breast cancer.

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor (AI) improves invasive disease–free survival vs AI alone in HR+, HER2– early breast cancer.

Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication while reducing drug waste.

Courtney Moore, APRN, FNP-C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– disease.

The FDA has approved imlunestrant for the treatment of patients with ESR1-mutated ER+, HER2- metastatic breast cancer.

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median injection time of 2 minutes.

Courtney Moore, APRN, FNP-C, OCN, discusses how patient comorbidities and adverse effect profiles guide CDK4/6 inhibitor choice in the first-line setting.

Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors.

Familiarity with each component of antibody-drug conjugates helps nurses and APPs deliver proactive adverse event management to patients with cancer.

Catering supportive care to the individual being treated helps better meet the needs of each patient, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

Experts share advice on tailoring frontline treatment and managing toxicities for individuals with hormone receptor–positive metastatic breast cancer.

Kelsey Martin, APRN, AG-ACNP-BC, AOCNP, discusses current ADCs in breast, bladder, and lung cancer and highlights promising agents in development.

Nurse practitioners give their advice on making treatment choices based on the patient’s medical history and preferences.

Paolo Tarantino, MD, PhD, discusses ADC structure, toxicity, and nursing consideration for the treatment of patients with breast cancer.

Melissa Rikal, MSN, FNP-BC, AOCNP, shares strategies to help nurses improve adherence and patient education for oral oncolytic therapies.

Melissa Rikal, MSN, FNP-BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

Oncology nurses play a key role in monitoring, managing, and personalizing CDK4/6 inhibitor treatment to minimize toxicities and protect quality of life, according to Courtney Moore, APRN, FNP-C, OCN.

A breast cancer survivorship expert shares her top advice for counseling patients on endocrine therapy at the 5-year mark.

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in patients with breast cancer.

Adding aprepitant to chemotherapy was linked to longer survival in patients with non-luminal breast cancers, especially triple-negative breast cancer.

Pooled data from early-phase trials suggest JSKN003 is tolerable and active in patients with heavily pretreated HER2-positive disease.

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the care of HR+, HER2- mBC.

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.